Skip to main content
Equibles
ELDN logo

ELDN · Eledon Pharmaceuticals, Inc.

Track ELDN — free

Use ELDN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ELDN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.52 -0.03 (-0.85%) At close · Aug 20
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“management has concluded that substantial doubt exists about our ability to continue as a going concern. Although management intends to obtain additional financing through the sources described above, these plans are subject to market conditions and other factors outside our control. Accordingly, management has concluded that its plans do not alleviate the substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$287.26M
Shares
81.26M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.52 Open$3.53 Day$3.42–3.59 52W close$1.39–4.36 Avg vol 30d954K Short int6.2M · 7.6% float · 6.5d Short vol65% Last earningsNov 7, 2025 DataOct 2020–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Oct 5, 2020; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +21%
above
Price vs 50-day avg −5%
below
RSI (14) 45
neutral
MACD trend Positive
52-week position 72%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −6%
trailing
6-month return +34%
trailing
YTD return +133%
this year
Relative strength +23%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +48 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.65% of float · ▲ +12.5% MoM · 6.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 3-yr high, broad support
Squeeze score 75
high risk · 0–100
Fundamentals
Strong
EPS growth +21%
Y/Y
Free cash flow $-62.4M
Balance sheet $22.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −68%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+21% Bullish
Price vs 50-day avg
−5% Bearish
RSI (14)
45 Neutral
MACD trend
Positive Bullish
52-week position
72% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +48 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.65% of float · ▲ +12.5% MoM · 6.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $4 · 72% Range high $4
vs 200-day avg +21% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ELDN
Eledon Pharmaceuticals, Inc.
this stock
$287.26M +133.1% — — 7.6%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
159
% held
58.8%
Net QoQ
+5.0M sh
Top holder
BVF INC/IL
Held Float
View
Held by Funds
Fund positions
91
View
Short & Settlement
Short Interest Rising
Shares short
6.2M
Days to cover
6.5d
Change
+690.6K sh
View
Short Volume
Short vol %
65%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
3.3K
Value
$11.1K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
47.9%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-45.6M
EPS diluted
$-0.52
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
9
View
Exempt Offerings
Offering
Indefinite
Filed
May 23, 2024
View
Earnings & Events
Earnings Calls
Last call
Nov 7, 2025
View

Performance

Raw-price comparisons begin at the captured split on Oct 5, 2020; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
ELDN -4.9% -5.9% +34.4% +4.1% +133.1%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY -2.9% -9.2% +23.2% +2.1% +121.3%
Key facts CIK 1404281 CUSIP 28617K101 13F (30d) 144 filings 140 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)